BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25948795)

  • 1. [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer].
    Placer J; Planas J; Celma A; Morote J
    Arch Esp Urol; 2015 Apr; 68(3):210-28. PubMed ID: 25948795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of prostatic specific antigen (PSA) for diagnosis and staging of patients with prostate cancer].
    Placer J; Morote J
    Arch Esp Urol; 2011 Oct; 64(8):659-80. PubMed ID: 22052750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.
    Salman JW; Schoots IG; Carlsson SV; Jenster G; Roobol MJ
    Adv Exp Med Biol; 2015; 867():93-114. PubMed ID: 26530362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
    Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
    Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
    Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
    Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
    Zhang MZ; Lu YP
    Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].
    Houlgatte A; Vincendeau S; Desfemmes F; Ramirez J; Benoist N; Bensalah K; Durand X
    Prog Urol; 2012 May; 22(5):279-83. PubMed ID: 22515924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.